Innate Pharma (IPHA) Divestments (2019 - 2025)

Innate Pharma (IPHA) has reported Divestments for 7 consecutive years, with $8.3 million the latest figure, recorded in Q4 2025.

• Quarterly Divestments fell 20.77% year-over-year to $8.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $42.0 million (up 17.2% YoY) and the FY2025 annual result came in at $8.3 million, down 20.77% from the prior year.
• Divestments declined to $8.3 million in Q4 2025 per IPHA's latest filing, from $10.5 million in the prior quarter.
• Over the last five years, Divestments for IPHA reached as high as $23.5 million in Q4 2023 and fell as low as -$1.0 million in Q4 2021.
• A 5-year average of $5.3 million and a median of $928001.7 in 2022 frame the typical range for Divestments.
• Annual changes were most pronounced in 2022 — Divestments slumped 59.92% — and 2023, when it soared 999.09%.
• Year by year, Divestments stood at -$1.0 million in 2021, then soared by 304.69% to $2.1 million in 2022, then surged by 999.09% to $23.5 million in 2023, then tumbled by 55.4% to $10.5 million in 2024, then slipped by 20.77% to $8.3 million in 2025.
• According to Business Quant data, Divestments over the past three periods registered $8.3 million, $10.5 million, and $23.5 million for Q4 2025, Q4 2024, and Q4 2023 respectively.